Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The lymphatic system, specifically the sentinel lymph node (SLN), is an anatomical target critical for oncologic staging. The SLN is the first lymph node or group of nodes to which cancer cells are most likely to spread from a primary tumor. Localization techniques, such as dual-modality imaging using Tc-99m radiocolloid and blue dye, or fluorescence-guided surgery with ICG, are used to identify and biopsy the SLN. This allows for accurate assessment of regional metastasis and informs treatment decisions, potentially avoiding more extensive surgical procedures like full nodal dissection.
Tc-99m radiocolloid: Radioactive tracer for lymphoscintigraphy. Blue dye: Visual tracer for intraoperative identification. ICG: Near-infrared dye for fluorescence-guided surgery.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lymphatic System (Sentinel Lymph Node Localization) (SLN).